Clinical trials: Lung Cancer Symptoms
Metastatic Cancer
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant.
- Trial name
- NCT00861107
- Testing
- AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mirror Biologics, Inc.
Metastatic Cancer
Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic Cancer
Nivolumab is a selective monoclonal antibody that binds to the Programmed cell Death 1 (PD-1) receptor and causes reduced tumor growth. It is currently approved in France in many indications.
- Trial name
- IMEPOCA (NCT05380336)
- Where
- France
- Volunteers
- 40,000 people
- Sponsor
- Nantes University Hospital
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Fatigue, Self Efficacy
Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience
Among 13 core symptoms across 3,106 breast, colorectal, prostate, and lung cancer patients, persons with lung cancer were the most symptomatic, with moderate to severe fatigue being reported with the greatest prevalence.
- Conditions
- Fatigue, Self Efficacy, Quality of Life, Physical Activity
- Trial name
- NCT03724331
- Testing
- Light Physical Activity 1, Light Physical Activity 2, Support Education Activity
- Where
- United States
- Volunteers
- 235 people
- Sponsor
- University of Nebraska
Lung Cancer, Lung Cancer (Diagnosis)
Evaluation of the Synergistic Impact of Needle and Forceps Biopsy With Electromagnetic Navigation Bronchoscopy
This randomized crossover study aimed to evaluate whether a multimodal biopsy strategy using both needle and forceps can provide additive benefits compared with a single device for diagnosing peripheral pulmonary lesions with…
- Trial name
- NCT05110131
- Testing
- Device for performing biopsy via electromagnetic navigation bronchoscopy
- Where
- South Korea
- Volunteers
- 142 people
- Sponsor
- Seoul National University Bundang Hospital
Lung Cancer
Molecular Mechanism of Trophinin in Cancer Invasion and Metastasis
Our study established a model combine the in silico biology and empirical methods to identify clinically useful biomarker from information of microarray gene expression profiles in public domain.
- Trial name
- NCT00166972
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Infiltrate New
FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary infiltrates frequently complicate the care of hematopoietic stem cell transplant (HSCT) and leukemia patients. Bronchoalveolar lavage (BAL) is frequently used to evaluate new pulmonary infiltrates in this population…
- Trial name
- NCT01328873
- Testing
- Microbiological analysis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northside Hospital, Inc.
Chemotherapy-induced Nausea and Vomiting
Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
This study evaluates the possibility to reduce the total dose of dexamethasone, when administered with NEPA, to prevent chemotherapy-induced nausea and vomiting (CINV) in Non-Small Cell Lung Cancer (NSCLC) patients receiving a…
- Trial name
- LUNG-NEPA (NCT04201769)
- Testing
- Netupitant/Palonosetron, Dexamethasone
- Where
- 26 sites in Italy
- Volunteers
- 261 people
- Sponsor
- Consorzio Oncotech
Colorectal Cancer, Non Small Cell Lung Cancer
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients.
- Trial name
- COPE (NCT04258137)
- Testing
- Liquid biopsy
- Where
- 6 sites in France
- Volunteers
- 332 people
- Sponsor
- Institut Bergonié
Osteosarcoma Metastatic
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma…
- Trial name
- NCT00102531
- Testing
- Cisplatin liposomal
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Insmed Incorporated
Lung Cancer, Metastatic Cancer
WBRT & Erlotinib in Advanced NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- TACTIC (NCT00554775)
- Testing
- erlotinib hydrochloride
- Where
- 7 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Lung Cancer, Pulmonary Neoplasms
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
To demonstrate an increase in overall survival for patients with newly diagnosed extended stage small cell lung cancer when treated with SR48692 versus placebo, after an initial response (complete or partial response or stable)…
- Conditions
- Lung Cancer, Pulmonary Neoplasms, Small Cell Lung Cancer
- Trial name
- SESAME (NCT00290953)
- Testing
- SR48692
- Where
- 14 sites in Argentina, Australia and 12 more
- Volunteers
- 432 people
- Sponsor
- Sanofi
Cardiovascular Diseases, Chronic Obstructive Pulmonary Diseases
The Efficacy and Safety of Electronic Cigarettes: a 5-year Follow-up Study
The main aim of this multicentric 5-year follow-up study is to evaluate for the first time the long-term efficacy and safety (in terms of smoking-related serious diseases requiring hospitalization) of e-cigarette smoking…
- Conditions
- Cardiovascular Diseases, Chronic Obstructive Pulmonary Diseases, Cancer of the Lung, Cancer of the Bladder
- Trial name
- NCT01785537
- Where
- Italy
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Cardiotoxicity
Effect of Trimetazidine on Radiotherapy-induced Heart Damage.
This is a randomized controlled trial. 80 patients with thoracic radiotherapy will be included. Participants will be randomly divided into experimental group or control group.
- Trial name
- NCT04939857
- Testing
- Trimetazidine
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
NSCLC, Stage I, II, III
A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.
Adding immune checkpoint inhibitors or molecularly targeted drugs as adjuvant therapy to curative treatments-such as surgery or chemoradiotherapy-for stage I-III non-small cell lung cancer (NSCLC) has been established as a…
- Trial name
- MRDSEEKER (NCT06854939)
- Where
- Japan
- Volunteers
- 350 people
- Sponsor
- National Cancer Center, Japan
Non-small Cell Lung Caner, KRAS-mutated
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner
- Conditions
- Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted
- Trial name
- NCT07562581
- Testing
- luvometinib + anlotinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Lung Cancer
A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer
Cancer patients are highly variable in their body composition, specifically in the proportion of fat and muscle. Some patients tend to gain fat and lose muscle (or lean body mass) at the same time.
- Trial name
- NCT01624051
- Testing
- Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area, Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- AHS Cancer Control Alberta
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one…
- Trial name
- NCT00769067
- Testing
- Erlotinib, PF-00299804
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.